Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity

Executive Summary

In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.


Related Content

Bristol’s Opdivo Is First Checkpoint Inhibitor Cleared For Blood Cancer
Celgene Diversifying Beyond Myeloma Backbone Revlimid
Multiple Myeloma Market Snapshot: New Drugs And Big Changes
Merck's Keytruda Data Brighten Picture For PD-1 Inhibitors In Myeloma
In Buzz Of 2015 Pharma Dealmaking, Immuno-Oncology Is Queen Bee
AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?
Celgene Secures Revlimid Frontline Myeloma Approval
Acute Lymphoblastic Leukemia Poised To Be First, Fast Driver Of CAR Immunotherapy
Celgene’s Budding Blockbuster Abraxane Scoops Pancreatic Cancer Indication
Celgene Flexes Its Muscles


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts